CymaBay Therapeutics Inc. (CBAY) Stock Price Peaks at $17.10 During Trading


The closing price of CymaBay Therapeutics Inc. (NASDAQ: CBAY) was $16.52 for the day, down -2.36% from the previous closing price of $16.92. In other words, the price has decreased by -$0.40 from its previous closing price. On the day, 2916399 shares were traded. CBAY stock price reached its highest trading level at $17.10 during the session, while it also had its lowest trading level at $16.43.

Do You Know The Best Place To Find Gains In Volatile Markets?

In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.

Click here for full details and to join for free


Our analysis of CBAY’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 12.50 and its Current Ratio is at 12.50. In the meantime, Its Debt-to-Equity ratio is 0.92 whereas as Long-Term Debt/Eq ratio is at 0.92.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, UBS on August 14, 2023, initiated with a Buy rating and assigned the stock a target price of $18.

Insider Transactions:

Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 18 when McWherter Charles sold 21,746 shares for $11.47 per share. The transaction valued at 249,359 led to the insider holds 15,000 shares of the business.

Quinlan Paul T sold 5,000 shares of CBAY for $59,550 on Aug 15. The General Counsel now owns 0 shares after completing the transaction at $11.91 per share. On Aug 09, another insider, Menold Daniel, who serves as the Vice President, Finance of the company, sold 20,945 shares for $12.35 each. As a result, the insider received 258,744 and left with 0 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CBAY now has a Market Capitalization of 1.62B and an Enterprise Value of 1.51B. For the stock, the TTM Price-to-Sale (P/S) ratio is 60.23 while its Price-to-Book (P/B) ratio in mrq is 15.58. Its current Enterprise Value per Revenue stands at 48.59 whereas that against EBITDA is -23.91.

Stock Price History:

Over the past 52 weeks, CBAY has reached a high of $18.20, while it has fallen to a 52-week low of $3.15. The 50-Day Moving Average of the stock is 13.02, while the 200-Day Moving Average is calculated to be 9.31.

Shares Statistics:

CBAY traded an average of 2.50M shares per day over the past three months and 4.28M shares per day over the past ten days. A total of 110.36M shares are outstanding, with a floating share count of 104.53M. Insiders hold about 0.31% of the company’s shares, while institutions hold 76.30% stake in the company. Shares short for CBAY as of Aug 30, 2023 were 8.96M with a Short Ratio of 8.96M, compared to 11.43M on Jul 30, 2023. Therefore, it implies a Short% of Shares Outstanding of 9.13% and a Short% of Float of 10.82%.

Earnings Estimates

The firm’s stock currently is rated by 13 analysts. On average, analysts expect EPS of -$0.3 for the current quarter, with a high estimate of -$0.25 and a low estimate of -$0.34, while EPS last year was -$0.28. The consensus estimate for the next quarter is -$0.31, with high estimates of -$0.24 and low estimates of -$0.37.

Analysts are recommending an EPS of between -$0.84 and -$1.02 for the fiscal current year, implying an average EPS of -$0.93. EPS for the following year is -$1.37, with 12 analysts recommending between -$0.99 and -$2.02.


Please enter your comment!
Please enter your name here